Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Patients with metastatic colorectal cancer (mCRC) who have received all approved standard
treatments (except Regorafenib and TAS 102) no longer have treatment options available while
maintaining a good performance status which would allow them to receive a new treatment